Sigrid Klaar

3.5k citations

17 papers · 2.6k indexed · 2 hit papers · h-index 12

Molecular Biology top 5%
Oncology top 2%
Cancer Research top 1%
Genetics top 10%
Pulmonary and Respiratory Medicine top 10%

Co-authors: Jonas Bergh Johanna Smeds Per Hall Alexander Ploner Yudi Pawitan Lance D. Miller Edison T. Liu Vinsensius B. Vega
Topics: Cancer-related Molecular Pathways (6 papers)HER2/EGFR in Cancer Research (5 papers)Cancer Genomics and Diagnostics (5 papers)
Cited by: Cancer Research Oncology Molecular Biology
Journals: Proceedings of the National Academy of Sciences Clinical Cancer Research Annals of Oncology
Partner nations: Sweden Singapore Finland

In The Last Decade

Sigrid Klaar

16 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival

2005 966 citations Lance D. Miller, Johanna Smeds et al. Proceedings of the National Academy of Sciences profile →
Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts

2005 613 citations Yudi Pawitan, Judith Bjöhle et al. Breast Cancer Research profile →

Peers

Countries citing papers authored by Sigrid Klaar

Since Specialization

Citations

This map shows the geographic impact of Sigrid Klaar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sigrid Klaar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sigrid Klaar more than expected).

Fields of papers citing papers by Sigrid Klaar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sigrid Klaar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sigrid Klaar. The network helps show where Sigrid Klaar may publish in the future.

Co-authorship network of co-authors of Sigrid Klaar

This figure shows the co-authorship network connecting the top 25 collaborators of Sigrid Klaar. A scholar is included among the top collaborators of Sigrid Klaar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sigrid Klaar. Sigrid Klaar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Changing views on adverse event reporting 2018 ·The Lancet Haematology ·(unknown),Sigrid Klaar,Daniel O’Connor	0
2	The European Medicines Agency Review of Eribulin for the Treatment of Patients with Locally Advanced or Metastatic Breast Cancer: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use 2012 ·Clinical Cancer Research ·(unknown),Sigrid Klaar,Eva Gil Berglund,Tomas Salmonson,Jeanett Borregaard,Kenneth Francis Hofland,Jens Ersbøll,Éric Abadie,Rosa Giuliani,Francesco Pignatti	28
3	Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcome 2007 ·Annals of Oncology ·Jenny Bergqvist,John Öhd,Johanna Smeds,Sigrid Klaar,Jorma Isola,Hans Nordgren,Göran Elmberger,Henrik Hellborg,Judith Bjöhle,Alexander Borg,Lambert Skoog,Jonas Bergh	31
4	Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients 2006 ·Breast Cancer Research ·Stefano Calza,Per Hall,Gert Auer,Judith Bjöhle,Sigrid Klaar,Ulrike Kronenwett,Edison T. Liu,Lance D. Miller,Alexander Ploner,Johanna Smeds,Jonas Bergh,Yudi Pawitan	205
5	Gene expression in 16q is associated with survival and differs between Sørlie breast cancer subtypes 2006 ·Genes Chromosomes and Cancer ·Kristian Wennmalm,Stefano Calza,Alexander Ploner,Per Hall,Judith Bjöhle,Sigrid Klaar,Johanna Smeds,Yudi Pawitan,Jonas Bergh	15
6	The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. 2006 ·Clinical Cancer Research ·Magali Olivier,(unknown),Patrizia Carrieri,Jonas Bergh,Sigrid Klaar,Jórunn E. Eyfjörd,Charles Theillet,Carmen Rodrı́guez,Rosette Lidereau,(unknown),Jennifer M. Varley,(unknown),Nancy Uhrhammer,Robert Winqvist,Arja Jukkola‐Vuorinen,Dieter Niederacher,Shunsuke Kato,Chikashi Ishioka,Pierre Hainaut,Anne-Lise B√∏rresen-Dale	439
7	An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survivalbreakdown → 2005 ·Proceedings of the National Academy of Sciences ·Lance D. Miller,Johanna Smeds,Joshy George,Vinsensius B. Vega,Liza A. Vergara,Alexander Ploner,Yudi Pawitan,Per Hall,Sigrid Klaar,Edison T. Liu,Jonas Bergh	966
8	Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohortsbreakdown → 2005 ·Breast Cancer Research ·Yudi Pawitan,Judith Bjöhle,Lukas C. Amler,(unknown),Suzanne Egyházi,Per Hall,Xia Han,Lars Holmberg,Fei Huang,Sigrid Klaar,Edison T. Liu,Lance D. Miller,Hans Nordgren,Alexander Ploner,Kerstin Sandelin,Peter Shaw,Johanna Smeds,Lambert Skoog,Sara Wedrén,Jonas Bergh	613
9	Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF 2005 ·Annals of Oncology ·J. Andersson,Lena Larsson,Sigrid Klaar,Lars Holmberg,Johan Nilsson,Mats Inganäs,Göran Carlsson,John Öhd,C.-M. Rudenstam,Bengt Gustavsson,Jonas Bergh	46
10	Gene profile and response to treatment 2005 ·Annals of Oncology ·Johanna Smeds,Lance D. Miller,Judith Bjöhle,Per Hall,Sigrid Klaar,(unknown),Yudi Pawitan,Alexander Ploner,Jonas Bergh	12
11	Skin toxicity as a risk factor for major infections in breast cancer patients treated with docetaxel 2004 ·Acta Oncologica ·Paula Poikonen‐Saksela,Johanna Sjöström,Sigrid Klaar,(unknown),Helgi Sigurðsson,Ebbe Lindegaard Madsen,Heikki Joensuu,Carl Blomqvist	5
12	Thrombospondin-1 expression in relation to p53 status and VEGF expression in human breast cancers 2004 ·European Journal of Cancer ·Barbro Linderholm,Eva Karlsson,Sigrid Klaar,Thomas Lindahl,(unknown),Göran Elmberger,Jonas Bergh	11
13	A Population-based Study on the First Forty-Eight Breast Cancer Patients Receiving Trastuzumab (Herceptin®) on a Named Patient Basis in Sweden 2002 ·Acta Oncologica ·J. Andersson,Barbro Linderholm,(unknown),Birgitta Lindh,Henrik Lindman,Jan Tennvall,Lena Tennvall-Nittby,(unknown),Ásgerður Sverrisdóttir,Martin Söderberg,Sigrid Klaar,Jonas Bergh	11
14	Increased p53 mutation frequency during tumor progression--results from a breast cancer cohort. 2001 ·PubMed ·Torbjörn Norberg,Sigrid Klaar,(unknown),Hans Nordgren,Lars Holmberg,Jonas Bergh	42
15	Enzymatic Mutation Detection Method Evaluated for Detection of p53 Mutations in cDNA from Breast Cancers 2001 ·Clinical Chemistry ·Torbjörn Norberg,Sigrid Klaar,(unknown),Thomas Lindahl,Johan Ahlgren,Jonas Bergh	5
16	The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. 2001 ·PubMed ·Barbro Linderholm,Thomas Lindahl,Lars Holmberg,Sigrid Klaar,Johan Lennerstrand,Roger Henriksson,Jonas Bergh	128
17	Can Axillary Dissection be Avoided by Improved Molecular Biological Diagnosis? 2000 ·Acta Oncologica ·Thomas Lindahl,Georg Engel,Johan Ahlgren,Sigrid Klaar,Judith Bjöhle,Henrik Lindman,J. Andersson,E. von Schoultz,Jonas Bergh	12

About Sigrid Klaar

Sigrid Klaar is a scholar working on Cancer Research, Oncology and Dermatology, having authored 17 papers that have together received 2.6k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (6 papers), HER2/EGFR in Cancer Research (5 papers) and Cancer Genomics and Diagnostics (5 papers). The work is most often cited by research in Cancer Research (1.1k citations), Oncology (1.2k citations) and Molecular Biology (1.7k citations). Sigrid Klaar has collaborated with scholars based in Sweden, Singapore and Finland. Frequent co-authors include Jonas Bergh, Johanna Smeds, Per Hall, Alexander Ploner, Yudi Pawitan, Lance D. Miller, Edison T. Liu, Vinsensius B. Vega, Joshy George and Liza A. Vergara. Their work appears in journals such as Proceedings of the National Academy of Sciences, Clinical Cancer Research and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact